ReviewAdvanced drug delivery reviews2019
Nanotechnology in cell replacement therapies for type 1 diabetes.
Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Human donor islets coated with functionalized chitosan and alginate nanoscale layers can restore normoglycemia in diabetic mice.Materials today. Bio · 2026Article
- Combined Use of Vitamin D and DPP-4 Inhibitors as a Potential Adjuvant Treatment Strategy to Enhance the Efficacy of Novel Beta-Cell Replacement Therapies for Type 1 Diabetes.Medical sciences (Basel, Switzerland) · 2025Review
- The role and mechanism of mesenchymal stem cells in immunomodulation of type 1 diabetes mellitus and its complications: recent research progress and challenges: a review.Stem cell research & therapy · 2025Review
- Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems.Pharmaceutics · 2025Review
- Smart transplants: emerging role of nanotechnology and big data in kidney and islet transplantation, a frontier in precision medicine.Frontiers in immunology · 2025Review
- Innovations in hydrogel therapies for diabetic wound healing: bridging the gap between pathophysiology and clinical application.Burns & trauma · 2025Review
- Immunoprotection Strategies in β-Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- A Glucose-Responsive Cannula for Automated and Electronics-Free Insulin Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.Stem cell reviews and reports · 2023Review
- Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.Stem cell reviews and reports · 2023Review
- Type 1Micromachines · 2023Review
- Type 1 diabetes and engineering enhanced islet transplantation.Advanced drug delivery reviews · 2022Review
- Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression.Science advances · 2022Article
- Therapeutic Effects of Insulin-Producing Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Type 1 Diabetes Mouse Model.International journal of molecular sciences · 2022Article
- A human pancreatic ECM hydrogel optimized for 3-D modeling of the islet microenvironment.Scientific reports · 2022Article
- Loading of Coal Tar in Polymeric Nanoparticles as a Potential Therapeutic Modality for Psoriasis.ACS omega · 2022Article
- A Safe, Fibrosis-Mitigating, and Scalable Encapsulation Device Supports Long-Term Function of Insulin-Producing Cells.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Emerging Theranostic Nanomaterials in Diabetes and Its Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Recent advances in the application of nanomedicine for the treatment of diabetes.Nanomedicine (London, England) · 2022Article
- Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Islet transplantation is a promising long-term, compliance-free, complication-preventing treatment for type 1 diabetes. However, islet transplantation is currently limited to a narrow set of patients due to the shortage of donor islets and side effects from immunosuppression. Encapsulating cells in an immunoisolating membrane can allow for their transplantation without the need for immunosuppression. Alternatively, "open" systems may improve islet health and function by allowing vascular ingrowth at clinically attractive sites. Many processes that enable graft success in both approaches occur at the nanoscale level-in this review we thus consider nanotechnology in cell replacement therapies for type 1 diabetes. A variety of biomaterial-based strategies at the nanometer range have emerged to promote immune-isolation or modulation, proangiogenic, or insulinotropic effects. Additionally, coating islets with nano-thin polymer films has burgeoned as an islet protection modality. Materials approaches that utilize nanoscale features manipulate biology at the molecular scale, offering unique solutions to the enduring challenges of islet transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.